The increase included an increase in personnel-related expenses of $3.9 million due to increased headcount and consulting costs, an increase of $3.0 million in clinical development costs, partially offset by a decrease of $1.6 million in non-clinical development costs associated with research and development program costs, supplies, and testing.

filing / Aug 10, 2026 / receipt

The increase included an increase of $2.3 million in clinical development costs and an increase in personnel-related expenses of $1.8 million due to increased headcount and consulting costs, partially offset by a decrease of $1.2 million in non-clinical development costs associated with research and development program costs, supplies, and testing.

filing / Aug 10, 2026 / receipt

Office Lease In August 2024, the Company entered into an additional addendum to the lease agreement for office space in New Hope, PA originally entered into by Orchestra BioMed, Inc.

filing / Aug 10, 2026 / receipt

In August 2024, the Company entered into an additional addendum to the lease agreement for office space in New Hope, PA originally entered into by Orchestra BioMed, Inc.

filing / Aug 10, 2026 / receipt

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2026.

filing / Aug 10, 2026 / receipt

The increase included an increase in personnel-related expenses of $2.1 million due to increased headcount and consulting costs, an increase of $632,000 in clinical development costs, partially offset by a decrease of $408,000 in non-clinical development costs associated with research and development program costs, supplies, and testing.

filing / May 12, 2026 / receipt

Office Lease In August 2024, the Company entered into an additional addendum to the lease agreement for office space in New Hope, PA originally entered into by Orchestra BioMed, Inc.

filing / May 12, 2026 / receipt

In August 2024, the Company entered into an additional addendum to the lease agreement for office space in New Hope, PA originally entered into by Orchestra BioMed, Inc.

filing / May 12, 2026 / receipt

Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.

filing / May 12, 2026 / receipt

Public Affairs, Research Internship (Fall 2026) | {"ats": "greenhouse", "city": null, "state": null, "job_id": "8806827002", "remote": false, "category": "other", "function": "other", "location": "New

company_statement / Sep 15, 2026 / receipt

Director, Experiential Production | {"ats": "greenhouse", "city": "New York, NY OR Los Angeles", "state": "CA", "job_id": "8805868002", "remote": false, "category": "other", "function": "operations",

company_statement / Sep 14, 2026 / receipt

Head of Agency Marketing | {"ats": "greenhouse", "city": null, "state": null, "job_id": "8806083002", "remote": false, "category": "other", "function": "marketing", "location": "New York, N.Y.", "job_

company_statement / Sep 14, 2026 / receipt